JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M705831200 on February 3, 2008

J. Biol. Chem., Vol. 283, Issue 15, 9666-9673, April 11, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
283/15/9666    most recent
M705831200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Kourimate, S.
Right arrow Articles by Costet, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kourimate, S.
Right arrow Articles by Costet, P.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Dual Mechanisms for the Fibrate-mediated Repression of Proprotein Convertase Subtilisin/Kexin Type 9*Formula

Sanae Kourimate{ddagger}1, Cédric Le May{ddagger}, Cédric Langhi{ddagger}, Anne Laure Jarnoux§, Khadija Ouguerram{ddagger}||, Yassine Zaïr{ddagger}**, Patrick Nguyen{ddagger}{ddagger}, Michel Krempf{ddagger}||**, Bertrand Cariou{ddagger}**, and Philippe Costet{ddagger}2

From the {ddagger}INSERM, U915, Nantes, F-44000 France, §INSERM, U539, Nantes, F-44000 France, the **Clinique d'Endocrinologie et Nutrition, l'Institut du Thorax, CHU de Nantes, Nantes, F-44000 France, the ||FacultédeMédecine, l'Institut du Thorax, Universitéde Nantes, Nantes, F-44000 France, the CRNH de Nantes, Nantes, F-44000 France, and the {ddagger}{ddagger}Ecole Nationale Vétérinaire de Nantes, Nantes, F-44000 France

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is associated with familial autosomal dominant hypercholesterolemia and is a natural inhibitor of the LDL receptor (LDLr). PCSK9 is degraded by other proprotein convertases: PC5/6A and furin. Both PCSK9 and the LDLr are up-regulated by the hypocholesterolemic statins. Thus, inhibitors or repressors of PCSK9 should amplify their beneficial effects. In the present study, we showed that PPAR{alpha} activation counteracts PCSK9 induction by statins by repressing PCSK9 promoter activity and by increasing PC5/6A and furin expression. Quantification of mRNA and protein levels showed that various fibrates decreased PCSK9 and increased PC5/6A and furin expression. Fenofibric acid (FA) reduced PCSK9 protein content in immortalized human hepatocytes (IHH) as well as its cellular secretion. FA suppressed PCSK9 induction by statins or by the liver X receptor agonist TO901317. PCSK9 repression is occurring at the promoter level. We showed that PC5/6A and furin fibrate-mediated up-regulation is PPAR{alpha}-dependent. As a functional test, we observed that FA increased by 30% the effect of pravastatin on the LDLr activity in vitro. In conclusion, fibrates simultaneously decreased PCSK9 expression while increasing PC5/6A and furin expression, indicating a broad action of PPAR{alpha} activation in proprotein convertase-mediated lipid homeostasis. Moreover, this study validates the functional relevance of a combined therapy associating PCSK9 repressors and statins.


Received for publication, July 16, 2007 , and in revised form, February 1, 2008.

* This work was supported in part by the Laboratoires Pierre Fabre, the Agence Nationale de la Recherche (Physiopathologies Humaines 2006 R0651ONS), the Fondation de France, Association de Langue Française pour l'Etude du Diabète et des Maladies Métaboliques, Programme National de Recherche-Maladies Cardiovasculaires 2006. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement"in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental data and Fig. S1.

1 Supported by the Centre de Recherche en Nutrition Humaine of Nantes and Région Pays de la Loire.

2 A Contrat d'Interface INSERM-CHU de Nantes. To whom correspondence should be addressed: INSERM, U915 CHU Hôtel Dieu, 3ENORD, 9, Quai Moncousu, 44000, Nantes, France. Tel.: 33(0)240087533; Fax: 33(0)240087544; E-mail: philippe.costet{at}univ-nantes.fr.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.